As the second most common cause of cancer-related death in the United States, metastatic colorectal cancer (mCRC) is a prevalent and lethal disease.1 We saw a rapid expansion of the drug armamentarium for mCRC around the turn of the century with successive FDA approvals of irinotecan (1998), oxaliplatin (2004), bevacizumab (2004), and cetuximab (2004) that incrementally increased median survival from approximately 9 to 12 months to over 2 years.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with UNC Rex
Contact UNC Rex, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack